Tafamidis

Pre-clinicalActive

2 views this week 0 watching💤 Quiet

Interest: 30/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Conditions

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

Trial Timeline

Jun 15, 2024 → Feb 20, 2026

NCT ID

NCT06393465

About Tafamidis

Tafamidis is a pre-clinical stage product being developed by Pfizer for Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM). The current trial status is active. This product is registered under clinical trial identifier NCT06393465. Target conditions include Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM).

What happened to similar drugs?

3 of 19 similar drugs in Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) were approved

Approved (3) Terminated (0) Active (16)

✅tafamidis megluminePfizerApproved

✅TafamidisPfizerApproved

✅AcoramidisBayerApproved

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄EplontersenAstraZenecaPhase 3

🔄Eplontersen + PlaceboAstraZenecaPhase 3

🔄NNC6019-0001 + Placebo (NNC6019-0001)Novo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06393465	Pre-clinical	Active	Jun 15, 2024	Feb 20, 2026	Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
NCT06086353	Pre-clinical	Completed	Mar 25, 2024	Jun 6, 2025	Transthyretin Amyloid Cardiomyopathy
NCT05139680	Pre-clinical	Completed	Mar 8, 2023	May 19, 2023	Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
NCT05560555	Pre-clinical	Completed	Oct 24, 2022	Nov 15, 2022	Hereditary Transthyretin Amyloidosis (ATTRv)
NCT04814186	Approved	Completed	Jul 22, 2021	Oct 16, 2023	Transthyretin Amyloid Cardiomyopathy
NCT03662191	Phase 1	Completed	Sep 28, 2018	Jan 10, 2019	Healthy Volunteers
NCT03280173	Phase 1	Completed	Sep 29, 2017	Feb 23, 2018	Healthy
NCT03266705	Phase 1	Completed	Sep 20, 2017	Mar 1, 2018	Healthy
NCT02791230	Phase 3	Completed	Jun 13, 2016	Nov 2, 2023	Transthyretin (TTR) Amyloid Cardiomyopathy
NCT02746926	Phase 1	Completed	Apr 29, 2016	Jul 15, 2016	Healthy
NCT02697864	Phase 1	Completed	Apr 1, 2016	Jun 1, 2016	Healthy
NCT01435655	Phase 3	Completed	Nov 1, 2011	Feb 1, 2014	Transthyretin Familial Amyloid Polyneuropathy
NCT00935012	Phase 3	Completed	Sep 30, 2009	Nov 20, 2019	ATTR-CM
NCT00925002	Phase 3	Completed	Aug 5, 2009	Jul 8, 2020	ATTR-PN

Competing Products

20 competing products in Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

See all competitors

Product	Company	Stage	Hype Score
Eplontersen Solution for Injection	AstraZeneca	Phase 1	29
Eplontersen + Placebo	AstraZeneca	Phase 3	44
Treatment of transthyretin (ATTR) amyloidosis in observational study setting	AstraZeneca	Pre-clinical	33
Eplontersen	AstraZeneca	Phase 3	47
Eplontersen + Placebo	AstraZeneca	Phase 3	44
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 3	47
NNC6019-0001	Novo Nordisk	Phase 2	39
NNC6019-0001 + Placebo (NNC6019-0001)	Novo Nordisk	Phase 2	35
Coramitug	Novo Nordisk	Phase 1	36
Tafamidis	Pfizer	Pre-clinical	26
tafamidis meglumine	Pfizer	Approved	43
Fx-1006A	Pfizer	Phase 2	35
Tafamidis	Pfizer	Phase 3	40
Tafamidis 61 milligrams	Pfizer	Pre-clinical	26
Treatment for TTR amyloidosis + Treatment for TTR amyloidosis	Pfizer	Pre-clinical	26
Vyndaqel	Pfizer	Pre-clinical	26
tafamidis	Pfizer	Phase 3	40
Tafamidis	Pfizer	Approved	43
Tafamidis	Pfizer	Pre-clinical	26
Vyndamax (tafamidis 61mg)	Pfizer	Pre-clinical	30